Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
Duriez
Patrick
P
Université du Droit et de la Santé de Lille 2, Faculté de Pharmacie, Physiologie, 3 rue du Professeur Laguesse, BP83, 59006 Lille, France. Patrick.Duriez@univ-lille2.fr
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D050197:Atherosclerosis / Q000503:physiopathology / Q000517:prevention & control; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D008076:Cholesterol, HDL / Q000187:drug effects* / Q000502:physiology; D008078:Cholesterol, LDL / Q000187:drug effects*; D050171:Dyslipidemias / Q000188:drug therapy*; D006331:Heart Diseases / Q000517:prevention & control; D006801:Humans; D023303:Oxazolidinones / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use; D012307:Risk Factors
D000924:Anticholesteremic Agents; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D023303:Oxazolidinones; D011804:Quinolines; C483909:torcetrapib; C530884:anacetrapib